Trials / Recruiting
RecruitingNCT05818683
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
A Phase 1b Study of JNJ-78278343, Targeting Human Kallikrein 2 (KLK2) in Combination With Other Agents for Metastatic Prostate Cancer
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to identify the recommended phase 2 regimen(s) RP2R(s) of pasritamig and combination regimens in Part 1 (dose escalation) and to determine safety at the putative RP2R(s) of pasritamig with the combination regimens in Part 2 (dose expansion).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pasritamig | Pasritamig will be administered. |
| DRUG | Cetrelimab | Cetrelimab will be administered by intravenous infusion. |
| DRUG | Cabazitaxel | Cabazitaxel will be administered by intravenous infusion. |
| DRUG | Docetaxel | Docetaxel will be administered by intravenous infusion. |
| DRUG | Apalutamide | Apalutamide will be administered orally. |
| DRUG | Enzalutamide | Enzalutamide will be administered orally. |
| DRUG | Darolutamide | Darolutamide will be administered orally. |
| DRUG | Abiraterone acetate plus prednisone (AAP) | Abiraterone acetate plus prednisone (AAP) will be administered orally. |
| DRUG | Lutetium Lu-177 vipivotide tetraxetan | Lutetium Lu-177 vipivotide tetraxetan will be administered intravenously. |
| DRUG | JNJ-101556143 | JNJ-101556143 will be administered orally. |
Timeline
- Start date
- 2023-04-26
- Primary completion
- 2027-08-31
- Completion
- 2028-05-23
- First posted
- 2023-04-19
- Last updated
- 2026-04-13
Locations
15 sites across 3 countries: United States, Australia, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05818683. Inclusion in this directory is not an endorsement.